Rights to antibody drug from China’s Keymed change hands in Gilead acquisition of Ouro
Sichuan-based Keymed expects to receive up to US$320 million as a result of deal involving its autoimmune disease treatment licensed in 2024
US biopharmaceutical company Gilead Sciences agreed to buy Ouro Medicines, which is developing an antibody-based medicine for autoimmune diseases licensed from China’s Keymed Biosciences, in a deal worth up to US$2.18 billion.
Under the agreement, Gilead Sciences would pay shareholders of US-based Ouro Medicines US$1.675 billion in cash upfront, plus up to US$500 million tied to milestone payments, according to an exchange filing on Tuesday.
The transaction aimed to speed up the global development of CM336, or OM336, an experimental treatment that could be the best-in-class T-cell-engaging antibody for autoimmune diseases, the filing said.
Ouro holds exclusive rights – licensed from Sichuan-based Keymed in 2024 – to develop, manufacture and commercialise CM336 outside mainland China, Hong Kong, Macau and Taiwan. In return, Keymed received upfront and near-term payments and a minority equity interest in Ouro, which now stood at about 15 per cent, according to a separate filing with the Hong Kong stock exchange.
On completion of the acquisition by Gilead, Keymed expects to receive about US$250 million in upfront cash, plus up to US$70 million in additional milestone payments, for a total potential payout of about US$320 million.